We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Ingevity's (NGVT) Earnings Top Estimates in Q3, Sales Miss
Read MoreHide Full Article
Ingevity Corporation (NGVT - Free Report) logged profits (attributable to stockholders) of $59.9 million or $1.41 per share in third-quarter 2019, up around 16% from $51.7 million or $1.16 a year ago.
Adjusted earnings per share for the reported quarter were $1.46, surpassing the Zacks Consensus Estimate of $1.42.
The company’s revenues rose roughly 16% year over year to $359.9 million in the quarter, but lagged the Zacks Consensus Estimate of $365.3 million.
Adjusted EBITDA climbed roughly 26% year over year to $114 million in the quarter. While the chemical maker faced challenges from weak market fundamentals in the quarter, it gained from its acquisition of the Capa caprolactone business.
Ingevity Corporation Price, Consensus and EPS Surprise
Revenues from the Performance Chemicals division rose around 7% year over year to $229.7 million in the quarter. Revenues were driven by the addition of the engineered polymers product line through the Capa caprolactone acquisition.
Revenues from the Performance Materials unit climbed around 35% to $130.2 million, driven by strong sales to automotive customers in China. The growth was also supported by strong growth in sales of the company’s solutions geared to meet the U.S. and Canadian automotive emission regulations.
Balance Sheet
Ingevity ended the quarter with cash and cash equivalents of $75.6 million, up around 31% year over year. Long-term debt was $1,294.4 million, up around 74%.
Outlook
Ingevity revised its sales guidance for 2019 to between $1.28 billion and $1.30 billion from its earlier expectation of $1.30 billion and $1.36 billion. It also revised its adjusted EBITDA guidance for the year to the band of $390-$400 million from its prior view of $390-$410 million.
Price Performance
Shares of Ingevity have lost 1.2% year to date, underperforming the industry’s 14.6% rise.
Zacks Rank & Key Picks
Ingevity currently carries a Zacks Rank #3 (Hold).
Agnico Eagle has a projected earnings growth rate of 158.6% for the current year. The company’s shares have rallied 53% in a year’s time.
Kinross has projected earnings growth rate of 170% for the current year. The company’s shares have surged around 77% in a year’s time.
Franco-Nevada has estimated earnings growth rate of 35.9% for the current year. The company’s shares have gained roughly 54% in a year’s time.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
Image: Bigstock
Ingevity's (NGVT) Earnings Top Estimates in Q3, Sales Miss
Ingevity Corporation (NGVT - Free Report) logged profits (attributable to stockholders) of $59.9 million or $1.41 per share in third-quarter 2019, up around 16% from $51.7 million or $1.16 a year ago.
Adjusted earnings per share for the reported quarter were $1.46, surpassing the Zacks Consensus Estimate of $1.42.
The company’s revenues rose roughly 16% year over year to $359.9 million in the quarter, but lagged the Zacks Consensus Estimate of $365.3 million.
Adjusted EBITDA climbed roughly 26% year over year to $114 million in the quarter. While the chemical maker faced challenges from weak market fundamentals in the quarter, it gained from its acquisition of the Capa caprolactone business.
Ingevity Corporation Price, Consensus and EPS Surprise
Ingevity Corporation price-consensus-eps-surprise-chart | Ingevity Corporation Quote
Segment Review
Revenues from the Performance Chemicals division rose around 7% year over year to $229.7 million in the quarter. Revenues were driven by the addition of the engineered polymers product line through the Capa caprolactone acquisition.
Revenues from the Performance Materials unit climbed around 35% to $130.2 million, driven by strong sales to automotive customers in China. The growth was also supported by strong growth in sales of the company’s solutions geared to meet the U.S. and Canadian automotive emission regulations.
Balance Sheet
Ingevity ended the quarter with cash and cash equivalents of $75.6 million, up around 31% year over year. Long-term debt was $1,294.4 million, up around 74%.
Outlook
Ingevity revised its sales guidance for 2019 to between $1.28 billion and $1.30 billion from its earlier expectation of $1.30 billion and $1.36 billion. It also revised its adjusted EBITDA guidance for the year to the band of $390-$400 million from its prior view of $390-$410 million.
Price Performance
Shares of Ingevity have lost 1.2% year to date, underperforming the industry’s 14.6% rise.
Zacks Rank & Key Picks
Ingevity currently carries a Zacks Rank #3 (Hold).
Better-ranked stocks worth a look in the basic materials space include Agnico Eagle Mines Limited (AEM - Free Report) , Kinross Gold Corporation (KGC - Free Report) and Franco-Nevada Corporation (FNV - Free Report) , all sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Agnico Eagle has a projected earnings growth rate of 158.6% for the current year. The company’s shares have rallied 53% in a year’s time.
Kinross has projected earnings growth rate of 170% for the current year. The company’s shares have surged around 77% in a year’s time.
Franco-Nevada has estimated earnings growth rate of 35.9% for the current year. The company’s shares have gained roughly 54% in a year’s time.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
See their latest picks free >>